Myla Lai Goldman
Fondatore presso GeneCentric Therapeutics, Inc.
Posizioni attive di Myla Lai Goldman
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
Hatteras Venture Partners
 Hatteras Venture Partners Investment ManagersFinance Hatteras Venture Partners (Hatteras Venture) is venture capital firm founded in 2000 by Clay B. Thorp and John Crumpler. The firm is headquartered in Durham, North Carolina. | Investitore di Private Equity | - | - |
GeneCentric Therapeutics, Inc.
 GeneCentric Therapeutics, Inc. Medical SpecialtiesHealth Technology GeneCentric Therapeutics, Inc. develops and commercializes molecular diagnostic assays. Its product enables oncologists and patients to make more informed, individualized treatment decisions. The firm's product CSP identifies cancer subtypes that enable drug developers to meet the growing demand for precision medicines, and provide clinicians the information they need to make individualized treatment decisions. The company was founded by David Neil Hayes, Charles M. Perou, and Myla P. Lai-Goldman in 2011 and is headquartered in Durham, NC. | Presidente | 01/07/2021 | - |
| Fondatore | 01/07/2021 | - |
Storia della carriera di Myla Lai Goldman
Formazione di Myla Lai Goldman
| University of Pennsylvania | Graduate Degree |
| Columbia University Vagelos College of Physicians & Surgeons | Doctorate Degree |
Statistiche
Distribuzione geografica
| Stati Uniti | 5 |
Posizioni
| Graduate Degree | 1 |
| Private Equity Investor | 1 |
| Doctorate Degree | 1 |
Settori
| Consumer Services | 3 |
| Finance | 2 |
| Health Technology | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
| Aziende private | 2 |
|---|---|
Hatteras Venture Partners
Hatteras Venture Partners Investment ManagersFinance Hatteras Venture Partners (Hatteras Venture) is venture capital firm founded in 2000 by Clay B. Thorp and John Crumpler. The firm is headquartered in Durham, North Carolina. | Finance |
GeneCentric Therapeutics, Inc.
GeneCentric Therapeutics, Inc. Medical SpecialtiesHealth Technology GeneCentric Therapeutics, Inc. develops and commercializes molecular diagnostic assays. Its product enables oncologists and patients to make more informed, individualized treatment decisions. The firm's product CSP identifies cancer subtypes that enable drug developers to meet the growing demand for precision medicines, and provide clinicians the information they need to make individualized treatment decisions. The company was founded by David Neil Hayes, Charles M. Perou, and Myla P. Lai-Goldman in 2011 and is headquartered in Durham, NC. | Health Technology |
- Borsa valori
- Insiders
- Myla Lai Goldman
- Esperienza
